ASXL1 and acquired polycythemia vera: Guglielmelli, Coltro, and investigators reported in 2022 an analysis of 523 patients with MF at various disease stages, including primary myelofibrosis (PMF), pre-MF, and post-polycythemia vera (PPV-MF), in which ASXL1 mutations were identified in 157 (30%) of patients [63].